Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Focal Segmental Glomerulosclerosis - Pipeline Review, H2 2016, provides an overview of the Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Focal Segmental glomerulosclerosis is a rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. Symptoms include proteinuria, edema, high cholesterol, high blood pressure and poor appetite. Risk factors include infection, obesity, sickle cell disease and reflux nephropathy. Treatment includes antibiotics, vitamin D supplements, and immunosuppressive drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Focal Segmental Glomerulosclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Focal Segmental Glomerulosclerosis (FSGS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Focal Segmental Glomerulosclerosis (FSGS) Overview 6
Therapeutics Development 7
Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) - Overview 7
Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis 8
Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics under Development by Companies 9
Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics under Investigation by Universities/Institutes 10
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Focal Segmental Glomerulosclerosis (FSGS) - Products under Development by Companies 13
Focal Segmental Glomerulosclerosis (FSGS) - Products under Investigation by Universities/Institutes 14
Focal Segmental Glomerulosclerosis (FSGS) - Companies Involved in Therapeutics Development 15
Complexa Inc 15
Dimerix Bioscience Pty Ltd 16
GlaxoSmithKline Plc 17
Retrophin Inc 18
Shire Plc 19
Variant Pharmaceuticals Inc 20
Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 30
(irbesartan + propagermanium) - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CXA-10 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
losmapimod - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
SHP-627 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
sparsentan - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
TM-5484 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
VAR-200 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Focal Segmental Glomerulosclerosis (FSGS) - Dormant Projects 44
Focal Segmental Glomerulosclerosis (FSGS) - Discontinued Products 45
Focal Segmental Glomerulosclerosis (FSGS) - Product Development Milestones 46
Featured News & Press Releases 46
Nov 30, 2016: World Renowned Experts Join Variant Pharmaceuticals' Scientific Advisory Board 46
Nov 21, 2016: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 47
Nov 19, 2016: Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 48
Oct 21, 2016: Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016 49
Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis 51
Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA 51
Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis 52
Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease 53
Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis 54
Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan 54
Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin 55
Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016 7
Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Complexa Inc, H2 2016 15
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 16
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by GlaxoSmithKline Plc, H2 2016 17
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Retrophin Inc, H2 2016 18
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Shire Plc, H2 2016 19
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Variant Pharmaceuticals Inc, H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Assessment by Combination Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 29
Focal Segmental Glomerulosclerosis (FSGS) - Dormant Projects, H2 2016 44
Focal Segmental Glomerulosclerosis (FSGS) - Discontinued Products, H2 2016 45